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ABSTRACT
Experiments have been undertaken to determine the extent to which cholic acid conju-
gates of insulin were absorbed from the small intestine of anaesthetised rats by means
of the bile salt transporters of the ileum. The measure used to assess the absorption
of the cholyl-insulins was the amount of hypoglycaemia following infusion into the small
intestine. Control experiments involving infusion of natural insulin into the ileum showed
either nil absorption or absorption of a small amount of insulin as indicated by transient
dip in the blood glucose concentration. However, when insulin was co-infused with the
bile salt taurocholate, this was followed by a marked hypoglycaemic response which was
specific to the ileum and did not occur on infusion into the jejunum. When the two cholyl
conjugates of insulin were tested viz. B29-Lys-cholyl-insulin and B1-Phe-cholyl-insulin,
both were biologically active as indicated by hypoglycaemic responses on systemic in-
jection, though their potency was about 40% of that of natural insulin. While there
was no evidence for the absorption of B29-Lys-cholyl-insulin when infused into the ileum,
B1-Phe-cholyl-insulin did cause a long lasting hypoglycaemic response, indicating that
absorption had occurred. Since the hypoglycaemic response was blocked on co-infusion
with taurocholate and was absent for infusion of the conjugate into the jejunum, these
results were taken as evidence that B1-Phe-cholyl-insulin had been taken up by the ileal
bile salt transporters. This would indicate that B1-Phe-cholyl-insulin is worthy of further
investigation for use in an oral insulin formulation.
1. Introduction
Since its discovery in 1922, the hormone insulin has been administered by sub-cutaneous
injection for the treatment of diabetes mellitus (Type 1) which arises from the loss of the
β-cells of the Islets of Langerhans of the pancreas and the subsequent loss of insulin pro-
duction [1]. The diabetic patient suffers not only from uncontrolled blood glucose levels
but also, in the longer term, from vascular disease due to glycosylation of haemoglobin.
To this end, more intensive therapy involving at least 3 injections of insulin each day has
been shown to be beneficial in reducing the incidence of retinopathy and nephropathy
[2]. Compliance can, however, be compromised by an aversion to self-injection due to
discomfort, abscess formation, scarring and lipohypertrophy at the site of injection [3].
Hence, alternative methods of treatment in the form of power injection of insulin into
the skin with pressurised helium gas [4], through inhalation of fine particles of insulin for
absorption from the alveoli [5] and through pancreatic islet cell transplantation [6] have
been developed, though none of these has proved to be a successful replacement for insulin
injections. The most desirable method of delivery would be an oral formulation taken at
meal-time, though this is fraught with several major considerations. First, there is the
need for protection of the orally-ingested insulin against digestion by gastro-intestinal
proteases [7, 8, 9, 10]. Then, once delivered into the small intestine, there then arises the
not inconsiderable problem of promoting the absorption of such a large charged molecule
which consists of an A chain of 21 amino acids joined by 2 disulphide bridges to a B chain
of 30 amino acids, across the intestinal mucosa into the mucosal circulation. This would
have to occur repeatedly for several applications of the formulation per day, extending
over the individual’s life time, without the risk of cumulative damage to the intestinal
mucosa. Of critical importance would be the quantity and the timing of ingestion of
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the formulation relative to the meal to be consumed. Long term safety in terms of the
toxicology of the insulin delivery system and the innocuousness of non-absorbed insulin
in the colon would also need to be assured [11]. While an oral insulin formulation is
beset with many difficulties, there have nevertheless been numerous efforts over the past
decades towards reaching this goal. The consensus is that absorption of insulin from the
small intestine, when infused in a moderate dose in a saline vehicle, does not occur to
any significant extent in animal models [12, 13, 14, 15, 16, 17, 18 19, 20, 21, 22, 23, 24,
25, 26, 27, 28, 29, 30, 31, 32, 33, 34], though some uptake has been reported for jejunal
and ileal infusions in conscious rabbits [35] and with high luminal doses in rabbit [30]
and in rat [26, 36]. In the promotion of insulin uptake, the approaches can be divided
broadly into the promotion of delivery of natural insulin to maximise its concentration
at the small intestinal mucosa and through the uptake of covalently-bonded insulin.
1.1. Promotion of absorption of natural insulin
There have been numerous investigations involving different insulin formulations with
the purpose of promoting the absorption of natural insulin from the small intestine, as
shown in the summary presented in Table 1. In addition, there are also published re-
sults of clinical trials which do not impart specific details of the formulation adopted
e.g. ORMD-0801 [37] and there is some limited information available from the web sites
and press releases of pharmaceutical companies [38]. In general, the published results
for the different insulin carrier systems, with one exception in which insulin uptake was
reported only from the colon [33], have indicated considerable success. This is exempli-
fied by the outcome of the 36 studies involving animal models in which infusion of the
insulin formulation into the small intestine in vivo led to a reduction in the blood glu-
cose concentration by 49 ± 3 % with a duration of action of 3.4 ± 0.4 h (mean ± S.E.M.).
The routes by which insulin is absorbed across the small intestinal mucosa may be tran-
scellular or paracellular. The small intestinal epithelium consists of about 90% entero-
cytes and 10% goblet cells which secrete mucus. These are joined at their luminal border
by tight junctions which consist of interleaving loops of the protein occludin which can be
regulated to increase the pore diameter of the junctions [39]. In the ileum, there are also
M cells (membranous epithelial cells) which overlie the Peyer’s patches and which are
known to be able to take up macromolecules from the lumen [40]. Immunocytochemical
studies suggest that the major route for absorption of free insulin is by the transcellular
route through the enterocytes [41] in which macromolecules are taken up at the lumi-
nal membrane by phagocytosis or pinocytosis followed by exocytosis at the basolateral
membrane and absorption into the mesenteric circulation [42]. This route of absorption
is facilitated by co-infusion of insulin with cell-penetrating peptides [23, 43, 44] and bile
salt liposomes [45]. In addition, there may be uptake through pores in the mucosa which
form transiently as a consequence of the shedding of the enterocytes at the tips of the villi
[46]. By contrast, insulin nanoparticle absorption has been described as occurring by the
paracellular route through the tight junctions and intercellular clefts [47, 48, 49] and this
process is enhanced by permeant inhibitors of phosphatase [31]. However, it has been
claimed that, while nanoparticles do provide protection against the action of intestinal
proteases, there was no resulting enhancement of absorption [50]. Also, the paracellu-
lar route is not the only means of absorption since lauryl succinyl chitosan also passes
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transcellularly [25], while poly(-²-caprolactone) is absorbed specifically by the Peyer’s
patches [51] and, in the case of vitamin B12-linked nanoparticles, absorption would be by
the vitamin B12 transporters which are located in the ileum [52].
Table 1
Summary of strategies to promote absorption of natural insulin
Vehicle Constituent References
(i) Saline vehicle apoprotinin1 [20, 33, 34, 53]
bile salts [20, 33, 34, 53, 54]
bile salts and apoprotinin [34, 41, 53, 55]
bile salts and bicarbonate [54]
bile salts and fatty acid mixed micelles [29, 56]
bile salts, palmitic acid, tocopherol [19]
caproic acid [20]
cetomacrogol or 5-methoxysalicylate2 [27, 32]
hyaluronic acid [57, 58]
hyaluronidase3 [21]
oligo-arginine, penetratin4 [23, 43, 44]
permeant inhibitor of phosphatase [31]
phenylalanine derivatives [12]
zonulin occludin toxin5 [18]
(ii) Enteric-coated calcium phosphate [59]
cellulose acetate phthalate [60, 61, 62]
gelatin [63]
(iii) Liposomes glycocholate [24]
red cell ghosts or liposomes [11, 36]
(iv) Water/oil/water micro-emulsions [9, 46]
emulsions saturated or unsaturated fatty acids [17, 30, 64]
4CNAB6 [38, 65]
(v) Nano/micro chitosan [66]
particles chitosan/poly(γ-glutamic acid) [48, 63]
cyclodextrin polymethacrylic acid hydrogel [28]
hyaluron-coated fibrillar insulin [16]
isobutyl-2-cyanoacrylate [67, 68]
lauryl succinyl chitosan [25]
phosphatidylcholine [69]
poly(lactic acid)-pluronic acid [70]
polymethacrylic acid polyethylene glycol [22]
poly(-²-caprolactone) [51]
polymerised fumaric acid and sebacic acid [71]
trimethyl chitosan [49]
vitamin B12-linked dextran-epichlorohydrin [15]
vitamin B12-linked polyallylamine [72]
1 protease inhibitor, 2 surfactants, 3 pretreatment to degrade glycocalyx overlying mu-
cosal epithelial cells, 4 cell-penetrating peptides, 5 to open tight junctions, 6 monosodium
N-(4-chlorosalicyloyl)-4-aminobutyrate
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1.2. Absorption of covalently-bonded insulin
Investigations involving the absorption of covalently-bonded molecules have consisted of
the following.
(i) Insulin has been conjugated at its B1 -NH2 group or at both the B
1 and B29 NH2
groups with palmitic acid [73], caproic acid [13] and methoxy-polyethylene glycol (PEG)
[14] in order to increase lipid solubility in the enterocyte luminal membrane.
(ii) Conjugation of customised peptides at the C3 hydroxyl group of cholic acid has been
made with the purpose of promoting uptake by the bile salt transporters which are lo-
cated in the ileum [74]. This, however, was successful only for peptides of up to ten
amino acids [75]. Conjugation has also been undertaken at the C24 carboxyl group via a
γ glutamyl link, though uptake was limited to tetrapeptides and hexapeptides [76].
(iii) Direct conjugation to the C24 carboxyl group of cholic acid has been undertaken
with triiodothyronine, though the purpose in this case was to reduce the uptake by the
heart since triiodothyronine is already absorbable from the small intestine [77]. Success-
ful absorption of a carbohydrate molecule in the form of heparin which was conjugated at
an amine group to the C24 carboxyl group of deoxycholic acid has also been reported [78].
In our experiments into the absorption of gastro-intestinal hormones from the small
intestine of anaesthetised rats, we conjugated the hormone directly to the C24 carboxyl
group of cholic acid. Conjugation was made directly to the N terminus of the 34 amino
acid hormone gastrin which stimulates gastric HCl secretion [79] and the 27 amino acid
hormone secretin which stimulates pancreatic HCO−3 secretion [80]. Conjugation had the
effect of increasing the biological activity of gastrin while that of secretin was reduced.
However, in both cases, appreciable absorption of the cholyl-gastrin and cholyl-secretin
was recorded with the latter achieving a bio-availability of 20-37% [80]. Since the uptake
was specific to the ileum and did not occur from the jejunum and since it was blocked by
co-infusion with taurocholate which was used as a competitive inhibitor, we concluded
that the cholyl hormone derivatives had been absorbed by the bile salt transporters.
It is this approach which we now extend to the absorption of cholyl-insulin. In the
initial experiments, we investigated the A21,20-S-S-B19-26 decapeptide of insulin and
its B19-Cys-cholyl-derivative since these were amenable to chemical synthesis and the
insulin decapeptide has been reported to possess 77% insulin activity [81]. However, the
decapeptides proved to be devoid of biological activity and, so, we then tested the extent
to which there was absorption of the cholyl derivatives of the full insulin molecule which
possesses three free -NH2 groups. Since the A
1-Glycine residue is required for hormone
activity [82], we tested the absorption of, first, B29-Lys-cholyl-insulin and, second, B1-
Phe-cholyl-insulin. Experiments were also undertaken to assess the absorption of natural
insulin in order to provide a reference for the cholyl-insulin experiments.
5
2. Materials and methods
2.1. Surgical procedures
Experiments were carried out on male Wistar rats, weight 240-360 g in accordance with
the Animals (Scientific Procedures) Act 1986. The animals were fasted overnight but
were allowed a 5% sucrose drink in addition to water. They were anaesthetised with an
intra-peritoneal (I.P.) injection of pentobarbitone sodium (Rhoˆne Me´rieux, Harlow, UK)
at a dose of 80 mg kg−1. The criterion for anaesthesia was abolition of the hind limb
flexor withdrawal reflex. In order to maintain the level of anaesthesia, supplementary
I.P. injections (24 mg kg−1) were given as required. At the end of the experiments, the
animals were killed with an intra-venous (I.V.) or intra-arterial (I.A.) injection of 100 mg
Euthatal (Merial Animal Health, Harlow, UK).
The initial surgical procedures consisted of tracheostomy to allow tracheal aspiration and
artificial ventilation, if necessary, and cannulation of the carotid artery with a Portex can-
nula of outer diameter 1.0 mm to monitor the arterial blood pressure. This was followed
by cannulation of the external iliac vein with a cannula of outer diameter 1.0 mm or
of the external iliac artery with a cannula of outer diameter 0.75 mm in order to allow
blood sampling or injection of hormones. The cannulae contained heparinised saline at
100 I.U. heparin ml−1 (Leo Laboratories Ltd., Princes Risborough, UK). After a midline
laparotomy, the pyloro-duodenal junction was ligated to prevent entry of gastric contents
into the duodenum and hence the possible release of duodenal hormones. The terminal
ileum was cannulated with a perforated Portex cannula of 2.0 mm outer diameter which
extended from a point of entry in the wall of the proximal colon through the ileo-colic
junction into the ileum. The ileum was then gently infused under visual observation
with 0.5 mL saline solution at 37oC, which was followed by slow withdrawal to remove
any bile and residual digestive matter. This process was repeated until the effluent was
clear. In some cases, an outlet cannula of 4 mm outer diameter was inserted 15 cm from
the inlet cannula to facilitate flushing. When jejunal cannulation was required, this was
undertaken with a perforated Portex cannula of 2.0 mm outer diameter with a point of
entry just distal to the ligament of Treitz. In these cases, the small intestine was also
ligated ca. 30cm from the ileo-colic junction to prevent entry of the jejunal infusate into
the ileum. The jejunum was also flushed with warm saline solution to remove the lumi-
nal contents. Some animals had both ileal and jejunal loops. Finally, bilateral cervical
vagotomy was undertaken to remove vago-vagal reflexes. The animal’s temperature was
maintained as near as possible to 37oC and, at the end of the experiment, samples of the
ileal/jejunal loops were taken for histology.
2.2. Blood samples
Blood glucose measurements were made in duplicate, with further samples taken if the
duplicates differed appreciably, using the Accu-Chek glucose meter (Roche Diagnostics,
Burgess Hill, UK) which was calibrated with the manufacturer’s calibration solutions.
Blood samples were obtained initially from the external iliac artery or vein and then by
incision of the tail artery. In the former, 2 small samples of 0.2 mL blood were withdrawn
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and the second sample was assayed: unused blood was then returned followed by a small
saline flush. In the latter, the first drop of blood was removed and the second drop
assayed. The incision was then sealed with surgical tape. In 4 experiments, sufficient
blood was withdrawn systemically to allow a parallel photometric assay using glucose
oxidase and dianisidine (Sigma GAGO-20,; Sigma, Poole, UK). For 40 samples with a
range of glucose concentrations of 0.5 to 9 mM, there was strong correlation between
the two assays (r = 0.96, P < 0.001), which confirmed the suitability of the Accu-Chek
glucose meter. In 7 experiments, one of which is shown in Fig. 1, comparisons were made
between parallel Accu-Chek glucose readings covering a range of 2 to 9 mM taken from
21 pairs of deep arterial and tail artery samples. These also showed a highly significant
correlation (r = 0.99, P < 0.001) and confirmed the suitably of tail artery sampling
which had the advantage of causing less disturbance to the arterial blood pressure.
2.3. Injections and infusions
I.A. or I.V. injections of hormones were made with the hormone dissolved in 0.1 mL
saline and were followed by 0.2 mL saline to flush through the cannula. For intra-ileal
or intra-jejunal infusions, the appropriate weight of hormone was dissolved in 1.0 ml
saline which was either phosphate buffered saline (147 mM NaCl, 3.0 mM Na2HPO4) or
citrate-phosphate saline (144 mM NaCl, 3.0 mM Na2HPO4, 1.0 mM citric acid) with the
purpose of chelating any zinc ions to preclude the possibility of hexamer formation [83].
The pH of the saline was set to 8.2 at a temperature of 37oC and was infused slowly
over a period of 3 min when it was followed by a wash-in infusion of 0.2 ml saline. In
control experiments, slow infusions of 1.0 mL saline at pH 8.2 were also made. The rate
of absorption of fluid from the intestinal loop was also monitored by visual inspection
at 30 min intervals. In some experiments, co-infusions were made with 20 mM sodium
taurocholate (Sigma T-4009) which is the main bile salt in the rat [84], with the dose of
20 mM being at the lower end of the normal range in natural bile [85]. Protease inhibitors
were not used in the experiments.
2.4. Insulin conjugates
Since insulin is a highly conserved hormone with only small differences between species
[86], we were not constrained by the source of the insulin and control experiments were
made with human recombinant insulin, molecular weight (MW) 5808 (Sigma I-9278).
Cholyl-insulin, MW 6124, was manufactured by the conjugation of bovine insulin (Sigma
I-5500) to cholic acid N -hydroxysuccinimide ester. Dimer and hexamer insulin self-
association was prevented by use of a citrate buffer. Conjugation with the C24 carboxyl
group of cholic acid was achieved at the B1-Phe NH2 residue by setting the insulin buffer
solution at pH 8.5 and at the B29-Lys NH2 residue with pH 10. Addition of small aliquots
of cholic acid-N -hydroxysuccinimide ester to the bovine insulin was followed by the ap-
propriate aliquots of NaOH solution which was used to maintain the pH throughout the
conjugation reaction. When an analytical hplc indicated the optimum reaction yield of
mono-conjugated insulin, the reaction was stopped and the cholyl-insulin precipitated
by acidification with HCl to pH 2-3. Preparative reversed-phase hplc was employed to
recover pure mono-conjugate and remove unconjugated and multiple conjugated insulin.
The purified material was freeze-dried and stored at -20oC. Insulin decapeptide (I10)
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(A21,20-S-S-B19-26, MW 1210)) and cholyl-insulin decapeptide (B19-Cys-cholyl-I10, MW
1600) were synthesised de novo by polymer-supported peptide synthesis techniques [79].
The MW of I10 and the cholyl-insulins was confirmed by mass spectrometry (MS) and
identification of the cholate binding site was undertaken by MS analysis of the products
of trypsin digest of the cholyl-insulin molecules.
2.5. Histology
As a standard procedure in the intestinal infusion experiments, a 5 cm length of small
intestine was resected immediately after termination of the experiment, infused with 10%
formal saline and immersed in 10% formal saline overnight. The tissue was then pro-
cessed for paraffin embedding and transverse sections were made at several locations in
each segment of gut. These were stained with haematoxylin/eosin and alcian blue for
light microscopy.
2.6. Data analysis
In addition to representative experiments from single animals, group results are presented
for the intestinal infusion experiments in the form of the mean ± S.E.M. normalised to
a control blood glucose concentration of 5.0 mM. Following an experimental procedure,
the hypoglycaemic response was measured as the decrement in the blood glucose con-
centration from the preceding baseline for each 15 min test period over the duration
of the response. If, instead of a level baseline, there was progressive hyperglycaemia,
e.g. Fig. 1, the response was obtained as the decrement from the best fitting regression
line derived from data values which occurred prior and subsequent to the response. An
overall response- the cumulative response- was then calculated as the summation of the
decrements at each 15 min test period. Tests against zero were made with the t-test
while comparisons of results between cohorts of animals were made with the two sample
t-test and within cohorts of animals with the paired t-test. Linear regression analysis was
undertaken to compare two sets of variables. The analyses were undertaken with Minitab
15 (Minitab UK, Coventry, UK) and statistical significance was taken as P < 0.05.
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3. Results
The present results were obtained from experiments of duration 6-8 h from a total of
114 rats in which the mean blood glucose concentration at the commencement of the
experiments was 5.1 ± 0.10 mM (mean ± S.E.M.). The abbreviations which have been
employed are: I.A. intra-arterial, I.V. intra-venous, I10 insulin decapeptide, I51 natural
insulin. The doses for systemic injections are given as nmol kg−1 while, in the specific
experiments illustrated in the Figures, the dose is that which was actually injected into
the animal in µg. The results are expressed throughout as the mean ± S.E.M.
The arterial blood pressure at the commencement of the experiments had mean sys-
tolic/diastolic values of 130/98 mmHg. The mean arterial blood pressure showed a mod-
est but significant reduction from 109 ± 1.36 mmHg at the commencement to 92 ± 1.67
mmHg at 5-8 h later (P < 0.001), while the corresponding values for the pulse pressure
of 32 ± 0.9 mmHg and 33 ± 1.3 mmHg were not significantly different (P = 0.45). There
was no discernible vascular action of insulin or cholyl-insulin when injected I.A. or I.V.
since the arterial blood pressure remained unaffected.
3.1. Control experiments
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Fig. 1. Representative control experiment from a single animal showing the blood glu-
cose levels (mM) while 3 intra-ileal infusions of 1.0 mL saline were given at 2 h intervals (S
and vertical dashed lines). Blood glucose values were obtained from both the tail artery
(solid circles) and the external iliac artery (inverted open triangles). The hyperglycaemic
increase between 240 and 360 min has superimposed upon it the line of best fit which
was highly significant (R2 = 99.4%, Pslope < 0.001).
Control experiments were undertaken in which the blood glucose concentration was fol-
lowed in the absence of experimental intervention in 5 animals and when intra-ileal in-
fusions of 1.0 mL saline were made during the course of the experiment in a further 2
animals (Fig. 1). The results were very similar in the 7 animals in that, after an initial
decline to a steady level, the blood glucose concentration remained reasonably constant
over the subsequent 2-3 h, after which it showed a slow progressive linear increase re-
sulting in an elevation of the blood glucose concentration by 1-3 mM after a further 3-4
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h. Fig. 1 also shows the close agreement between blood glucose concentrations obtained
from sampling from the tail artery and the external iliac artery.
3.2. Systemic injections
From preliminary dose-response experiments with systemic injections of the cholyl-insulins
I.A. or I.V., the minimum dose which evoked a discernible response was determined to be
1 nmol kg−1. From this we set our two standard doses at 2 nmol (0.33 I.U.) kg−1 and 20
nmol (3.3 I.U.) kg−1 so as to allow the hypoglycaemic activity of the cholyl-insulins to be
compared with that of natural insulin: the results are summarised in Table 2. As to be
expected, systemic injection of 2 nmol kg−1 natural insulin, which in this case was human
recombinant insulin, caused a marked hypoglycaemic response which, for 8 animals, had
a mean maximum reduction of -2.9 ± 0.20 mM and a duration of 11
2
h. At the 20 nmol
kg−1 dose, the hypoglycaemic response increased to -4.1 ± 0.31 mM with a prolonged
duration which was in excess of 3 h (Fig. 2a).
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Fig. 2. Representative experiments from 4 different animals showing the effects on
the blood glucose concentration (mM) of I.A. injections of (a) insulin (I51), (b) insulin
decapeptide (I10), (c) B29-Lys-cholyl-I51 (B29CI) and (d) B1-Phe-cholyl-I51 (B1CI). The
I.A. injections were at doses of 2.0 nmol kg−1 and 20 nmol kg−1 with the exception of
I10 (b) when the dose was 1.0 µmol kg−1. In (b), the responsiveness of the preparation
was confirmed with an I.A. injection of 3.5 µg I51.
By contrast, neither insulin decapeptide (I10) nor cholyl-I10 showed any response to the
two standard doses. Even when the dose was increased to 1.0 µmol kg−1 in 6 animals,
there was an absence of response to both I10 and cholyl-I10. Fig. 2b shows an example
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of an experiment with I.A. injection of I10 and is equally representative of the outcome
of the cholyl-I10 experiments. In all experiments, the responsiveness of the preparation
was confirmed from the response to 2 nmol kg−1 insulin I.A.
Table 2
Maximum and cumulative reductions in blood glucose concentration in response to stan-
dard doses of insulin and cholyl-insulin I.A.
2 nmol kg−1 2 nmol kg−1 20 nmol kg−1
n Maximum mM Cumulative mM n Maximum mM
I51 8 -2.9 ± 0.20 mM -11.4 ± 1.3 mM 8 -4.1 ± 0.31 mM
B29-Lys-cholyl-I51 6 -1.4 ± 0.22 mM∗∗ -4.9 ± 0.6 mM∗∗ 6 -5.0 ± 0.74 mM+
B1-Phe-cholyl-I51 6 -1.5 ± 0.22 mM∗∗ -4.0 ± 1.0 mM∗∗ 6 -4.2 ± 0.27 mM+
Reductions in blood glucose concentration indicated by negative values of the mean ± S.E.M.
Results are presented in terms of the maximum depression to each of the two doses and as the
cumulative response to the lower dose. The results for each conjugate were compared to the
insulin response with the two sample t-test: +P > 0.30, ∗∗P < 0.01.
Both the two cholic acid conjugates of the full insulin molecule, viz. B29-Lys-cholyl-I51
and B1-Phe-cholyl-I51, were biologically active, though with reduced efficacy compared
to that of natural insulin (Figures 2c & d, Table 2). In the 6 experiments in which the
2 nmol kg−1 dose was tested, the magnitude of the hypoglycaemic response in terms
of the cumulative depression of blood glucose was some 40% of that of natural insulin
(P < 0.01). By contrast, when the dose was increased to 20 nmol kg−1 (6 experiments),
the magnitude of the hypoglycaemic response to both conjugates increased markedly so
that it became indistinguishable from that caused by natural insulin (P > 0.30). The
response durations for both conjugates were also prolonged at this dose and were com-
parable to the durations for natural insulin (Fig. 2).
3.3. Intestinal infusions of insulin
Natural insulin at a dose of 0.7 mg (0.12 µmol) dissolved in 1.0 mL of phosphate buffered
saline at pH 8.2 was infused into the terminal ileum of 11 animals and the effects on the
blood glucose concentration was followed over several hours. These experiments were un-
dertaken after lavage of the ileum to remove any residual bile and, in some experiments,
the infusate also contained 1.0 mM citric acid to act as a Zn2+ chelating agent. The
normalised mean data showed a transient reduction in blood glucose concentration over
the period 30-75 min after infusion (Fig. 3) which was reflected in a small but significant
reduction in the cumulative blood glucose concentration of -2.2 ± 0.9 mM (P = 0.034,
Table 3). Further analysis, however, revealed 2 groups of results. In 6 animals, there
was an absence of a response (Fig. 4a) as confirmed by the non-significant cumulative
11
response of -0.3 ± 0.2 mM (P = 0.13) while in 5 animals, there was a significant cu-
mulative response of -4.4 ± 1.42 mM (P = 0.036) which extended over 60-90 min (Fig.
4b). There was, however, no ostensible reason for this dichotomy in that both groups
showed an intact mucosa under light microscopy, the time course of fluid absorption was
normal with a flaccid state being reached after 2 h, and there was no difference as to
whether phosphate buffered saline or citrate/phosphate buffered saline was employed.
In a further 7 experiments, the intra-ileal dose of insulin was increased to 2.7 mg (0.50
µmol) with the outcome that 6 animals showed zero response while one animal showed
a small hypoglycaemic dip of -1.2 mM over 30 min. Hence, overall, the outcome from
these experiments is that natural insulin is not generally absorbed from the ileum though,
occasionally, a small quantity may enter the systemic circulation.
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Fig. 3. Mean ± S.E.M. of blood glucose values normalised to a baseline level of 5.0 mM
shown by dotted horizontal line in response to: •-• 0.7 mg (0.12 µmol) insulin infused
intra-ileally (n = 11), N-N 0.7 mg insulin with 20 mM taurocholate infused intra-ileally
(n = 6), and H-H 0.7 mg insulin with 20 mM taurocholate infused intra-jejunally (n = 6).
Significant reduction from 5.0 mM is denoted by * (P < 0.05); otherwise there was no
significant difference (P > 0.05).
Since previous studies have indicated a facilitatory action of co-infusion of bile salts on
insulin uptake [41], this was investigated using 20 mM taurocholate in phosphate buffered
saline. As shown in Fig. 4c, control experiments in which taurocholate alone was infused
into the ileum showed the absence of an effect on the blood glucose level (P = 0.79, Ta-
ble 3). However, when 0.7 mg insulin co-infused with 20 mM taurocholate (Fig. 3, Fig.
4d, second infusion), there was a dramatic hypoglycaemic response in which the blood
glucose concentration was reduced by -3.3 ± 0.9 mM, P = 0.01) with a highly significant
cumulative reduction of -18.3 ± 4.2 mM (P = 0.01, Table 3). This hypoglycaemic re-
sponse was specific to the ileum since no such change was recorded on infusion into the
jejunum (Fig. 3, Fig. 4d, first infusion): the cumulative response of +2.1 ± 1.2 mM was
non-significant (P = 0.14, Table 3). The facilitatory action on insulin absorption from
the ileum also occurred at a much reduced dose of 0.5 mM taurocholate, though with a
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reduced response magnitude, and was also evident when prior lavage of the ileum was
not undertaken. This suggests that residual bile salts in the ileum may account for the
small hypoglycaemic response evident in some insulin experiments (Fig. 4b).
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Fig. 4. Representative experiments from 4 different animals showing blood glucose con-
centration (mM) after the stated intestinal infusions. (a) & (b) 0.7 mg (0.12 µmol) insulin
infused intra-ileally (I51 I.I.) (c) Control intra-ileal infusion of 20 mM Na taurocholate
(TCh) showing line of best fit for hyperglycaemic increase with R2 = 93.4%, Pslope <
0.001, after which responsiveness was confirmed by I.A. injection of 50 µg I51 (d) Co-
infusion of 0.7 mg I51 with 20 mM taurocholate, first, intra-jejunally (I51 I.J.) showing
line of best fit for hyperglycaemic increase with R2 = 92.5%, Pslope < 0.001 and, second,
intra-ileally (I51 I.I.).
3.4. Intestinal infusions of cholyl-insulins
Intra-ileal infusions of the B29-Lys-cholyl and B1-Phe-cholyl conjugates of insulin at a
dose equimolar to that of insulin (0.8 mg) dissolved in 1.0 mL of the phosphate or cit-
rate/phosphate buffered saline were then undertaken to determine the extent to which
they were absorbed across the ileal mucosa. As shown by the representative experiment
in Fig. 5a and normalised mean results in Fig. 6, B29-Lys-cholyl-insulin infused intra-
ileally in 7 animals was without a significant effect on blood glucose levels (P = 0.12,
Table 3). In these experiments, the responsiveness of the animal was always confirmed
by I.A. injection of conjugate at the end of the experiment.
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Table 3
Cumulative changes in blood glucose concentration (mM) after intestinal infusions
Infusate n mean ± S.E.M. P
0.7 mg Insulin I.I. 11 -2.2 ± 0.9 mM 0.034
20 mM TCh I.I. 6 -0.05 ± 0.8 mM 0.96
0.7 mg Insulin + TCh I.I. 6 -18.3 ± 4.2 mM 0.01
0.7 mg Insulin + TCh I.J. 6 +2.1 ± 1.22 mM 0.10
0.8 mg B29-Lys-cholyl-insulin I.I. 7 -3.3 ± 1.8 mM 0.12
0.8 mg B1-Phe-cholyl-insulin I.I. 7 -11.9 ± 1.1 mM 0.001
0.8 mg B1-Phe-cholyl-insulin + TCh I.I. 6 +0.4 ± 0.9 mM 0.65
0.8 mg B1-Phe-cholyl-insulin I.J. 5 +1.9 ± 0.9 mM 0.10
Cumulative change in blood glucose concentration as mean ± S.E.M. with - denoting hy-
poglycaemia and + denoting hyperglycaemia. I.J. intra-jejunal, I.I. intra-ileal, TCh 20 mM
taurocholate. P values are for t-test against zero.
By contrast, B1-Phe-cholyl-insulin infusion resulted in a marked hypoglycaemic response
which was evident by 30 min after infusion and lasted for 3 h or more (Figs. 5b & 6) and
the cumulative hypoglycaemic response of -11.9 ± 1.1 mM for the 7 animals tested was
highly significant (P = 0.001, Table 3). This cumulative response may, however, may
be an underestimate since, as shown in Fig. 5b, there is an indication that the hypogly-
caemic response became evident against a trend to progressive hyperglycaemia. In the
experiments, there was no discernible effect of the addition of citrate to the phosphate
buffered saline. The dose-dependance of the hypoglycaemic response was further investi-
gated in groups of 5 animals. At a 0.4 mg dose, the cumulative hypoglycaemic response
was -2.9 ± 0.7 mM while, at 1.6 mg, it was -6.9 ± 1.0 mM. Both were significantly lower
than the response to 0.8 mg (P < 0.01), indicating that 0.8 mg carried in 1.0 mL saline
was close to the optimal dose. The process by which B1-Phe-cholyl-insulin was absorbed
from the ileum is indicated by the results of the experiments involving co-infusion of the
conjugate with 20 mM taurocholate (Figs. 5c & 6) and the experiments in which the
conjugate was infused into the jejunum (Figs. 5d & 6). In each case, the hypoglycaemic
response was absent (P > 0.10, Table 3) which is consistent with the uptake of B1-Phe-
cholyl-insulin by the ileal bile salt transporters.
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Fig. 5. Blood glucose levels from 4 different experiments in response (a) intra-ileal
infusion of 0.8 mg B29-Lys-cholyl-insulin (CA I51 I.I.) followed by an I.A. dose of 3.1
µg cholyl-insulin (CA I51 I.A.) (b) intra-ileal infusion of 0.8 mg B1-Phe-cholyl-insulin
(CA I51 I.I.) followed by an I.A. dose of 80 µg cholyl insulin (CA I51 I.A.) (c) intra-ileal
infusion of 0.8 mg B1-Phe-cholyl-insulin in 20 mM taurocholate (CA I51 I.I.) followed by
I.A. dose of 3.5 µg to test responsiveness (CA I51 I.A.) (d) intra-jejunal infusion of 0.8 mg
B1-Phe-cholyl-insulin (CA I51 I.J.) followed by I.A. dose of 35 µg to test responsiveness
(CA I51 I.A.).
3.5. Histology of small intestinal mucosa
The results shown in Table 3 are based on experiments in which the small intestinal mu-
cosa showed a normal histological appearance in which the mucosa and villi were intact
(Fig. 7a). This was also the case when the infusate contained 20 mM taurocholate (Fig.
7b).
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Fig. 6. Mean ± S.E.M. of blood glucose values normalised to a baseline level of 5.0
mM shown by dotted horizontal line in response to: •-• 0.8 mg (0.12 µmol) B1-Phe-
cholyl-insulin infused intra-ileally (n = 7), N-N 0.8 mg B1-Phe-cholyl-insulin with 20 mM
taurocholate infused intra-ileally (n = 6), ◦-◦ 0.8 mg B1-Phe-cholyl-insulin infused intra-
jejunally (n = 5), and H-H 0.8 mg B29-Lys-cholyl-insulin infused intra-ileally (n = 7).
Significant reduction from 5.0 mM is denoted by * (P < 0.05); otherwise there was no
significant difference (P > 0.05).
(a) (b)
Fig. 7. Normal histology of ileal mucosa after experiments involving infusion of (a)
0.8 mg B1-Phe-cholyl-insulin in phosphate saline and (b) 0.8 mg B1-Phe-cholyl-insulin in
phosphate saline and 20 mM taurocholate. The lumen is at the top and the staining was
haematoxylin/eosin and alcian blue.
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4. Discussion
The major result from the present study is that conjugation of insulin at the free NH2
group at the B1-Phe position with the -COOH group at the C24 position of cholic acid
to form B1-Phe-cholyl-insulin promotes absorption from the ileum, while B29-Lys-cholyl-
insulin showed no indication of being absorbed (Figs. 5a, 5b & 6, Table 3). This result
was obtained in experiments in which the animals were shown to maintain a good physio-
logical condition throughout from their well maintained arterial blood pressure and from
the integrity of the ileal mucosa (Figs. 7a & b). As a precautionary measure, pyloric
ligation was undertaken to prevent the passage of chyme into the duodenum to avoid
the release of gastro-intestinal hormones viz. gastrin, cholecystokinin, secretin and gas-
tric inhibitory polypeptide, which have an insulinotropic action [87, 88, 89]. Bilateral
vagotomy was also undertaken since the vagus nerves stimulate insulin release [90]. Some-
times, there was the recurring feature of progressive hyperglycaemia which commenced
after 3-4 h, particularly in experiments which did not show a hypoglycaemic response
viz. the control experiments (Fig. 1), infusion of 20 mM taurocholate alone (Fig. 4c)
jejunal infusion experiments (Fig. 4d) and ileal infusion of B29-Lys-cholyl-insulin (Fig.
6). The reason is unlikely to be due to the anaesthetic since this only causes a transient
hyperglycaemia which subsides by 30 min post-injection [94], though it may account for
the initial settling of the blood glucose concentration seen in many experiments e.g. Fig.
1. The most likely cause of the delayed hyperglycaemia is surgery-induced ACTH re-
lease leading to increased systemic cortisol levels. Since cortisol acts genomically [95],
its effect in stimulating gluconeogenesis and antagonising insulin-stimulated glucose up-
take [96, 97] requires several hours to take effect after which blood glucose levels would
increase unless exogenous insulin was administered.
Systemic injections of natural insulin at the standard molar doses of 2 nmol kg−1 and 20
nmol kg−1 evoked marked hypoglycaemic responses which were especially prolonged at
the higher dose (Fig. 2a) and, on a dose per weight basis, are consistent with previously
published data in rat [91, 26], dog [29] and man [92]. This was in contrast to the in-
sulin decapeptide and its cholyl conjugate which, even at 500 times the standard insulin
molar dose, showed no evidence of biological activity (Fig. 2b) and is inconsistent with
the report that the insulin decapeptide possessed 77% of insulin activity [81]. This was
based on the promotion of glycogenesis in adipocytes in vitro and highlights the diffi-
culty in relating in vitro results to those from the intact animal in which the liver and
skeletal muscles have major roˆles in glucose uptake. By contrast, both the insulin con-
jugates, B29-Lys-cholyl-insulin and B1-Phe-cholyl-insulin, were shown to be biologically
active in that, when injected systemically, they caused a hypoglycaemic response which,
at the lower standard dose, amounted to some 40% of the insulin response, with a more
marked response of extended duration at the higher standard dose (Figs. 2c & d, Table
2). The only previous reports concerning cholyl-insulins relate to systemic injections of
B29-Lys-deoxycholyl-insulin which showed a slower onset and longer duration of action
than insulin [91] and sub-cutaneous injections of B29-Lys-lithocholyl-insulin which had
an enhanced duration of action [93].
For intra-ileal infusions of insulin, there was minimal absorption as shown by an absence
of a response or only a small transient hypoglycaemic dip of about 1 mM (Figs. 4a & b)
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which is consistent with previous studies (Introduction). This result was unaffected by
the inclusion of citrate as a Zn2+ chelator in the infusion saline, which excludes hexamer
formation as a reason for non-absorption of insulin [83]. There was, however, a very
dramatic change when insulin was co-infused with 20 mM taurocholate in that a very
marked and prolonged hypoglycaemic response was generated, indicating that apprecia-
ble amounts of insulin has been absorbed across the ileal mucosa, though this did not
occur with co-infusion into the jejunum (Figs. 3 & 4d, Table 3). This facilitatory action
of bile salts on insulin absorption is well documented [29, 34, 41, 53, 54, 55, 56], though
the absence of response on jejunal infusion has not previously been noted. The reasons
for this difference may stem from the presence in the ileum of Peyer’s patches, M cells or
bile salt transporters. In the event that the bile salt transporters are indeed involved, this
might be explained by the hydrophobic attraction of insulin to the bile salt, which would
then be taken up by the bile salt transporters. Irrespective of the actual mechanism, the
facilitatory action of residual bile salts may provide the explanation for those cases of
ileal infusion of insulin alone in which a small hypoglycaemic response in response was
recorded (Fig. 4b).
While intra-ileal infusion of B29-Lys-cholyl-insulin was without effect, there was an un-
equivocal hypoglycaemic response to infusion of B1-Phe-cholyl-insulin (Fig. 6, Table 3),
which is consistent with the absorption of the B1-Phe-cholyl-insulin into the systemic
circulation to promote the uptake of glucose by hepatic and muscle cells. While the ab-
sence of absorption of B29-Lys-cholyl-insulin is in part disappointing, these experiments
are useful for two reasons. The two conjugates are essentially identical chemically and
an absence of an effect with the B29-Lys conjugate supports the conclusion that the
B1-Phe conjugate was not being absorbed across the ileal mucosa by passive diffusion
or endocytosis. It also confirms that B1-Phe-cholyl-insulin was not acting through the
release of insulinotropic hormones from the ileum. Since the hypoglycaemic response
was abolished by co-infusion with 20 mM taurocholate into the ileum (Figs. 5c & 6)
and since the hypoglycaemic response was absent on infusion into the jejunum (Figs. 5d
& 6), this would be consistent with absorption of the B1-Phe-cholyl-insulin through the
bile salt transporters which are specific to the ileum [74]. This is plausible since insulin
has an overall negative charge [46], thus providing an anionic substrate for the bile salt
transporters which are Na+ dependent [98].
While rather approximate, there is an indication from a comparison of the intra-ileal
and intra-arterial cumulative hypoglycaemic responses (Fig. 5b) that the uptake of B1-
Phe-cholyl-insulin may amount to some 5-10% of the intra-ileal dose. However, this may
prove to be an underestimate given that the presumed baseline was sometimes equivocal
when the response coincided with the onset the delayed hyperglycaemia e.g. Fig. 5b.
These experiments were undertaken in normal animals after an overnight fast which was
necessary to allow emptying of the gastro-intestinal tract: the alternative of using fed
animals would, of necessity, involve additional disturbance to small intestine necessitated
by the flushing out of the compacted intestinal contents. During the fast, our animals
did have access to a sucrose drink which may be surmised to cause endogenous insulin
release in order to regulate their blood glucose levels. The fact that B1-Phe-cholyl-insulin
did cause sustained hypoglycaemic responses from normoglycaemic levels in our animals
(Fig. 6) may be taken as an encouraging sign for the next stage which would be to deter-
mine its effectiveness against uncontrolled hyperglycaemia in diabetic animals without
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endogenous insulin. Subsequently, it would then need to be established that the result
is transferable across the species barrier with the ultimate challenge being in human
subjects. In establishing that B1-Phe-cholyl-insulin was taken up by the ileal bile salt
transporters, the uptake was shown to be inhibited by co-infusion of 20 mM taurocholate
(Fig. 6), which introduces a potential complication in that, in the normally functioning
small intestine, endogenous bile salts would reduce the uptake of B1-Phe-cholyl-insulin
due to competition for sites on the bile salt transporters. However, the rat is unusual in
that it releases bile continuously into the duodenum due to the absence of a gall bladder
whereas, in man, bile is stored in the gall bladder and is released upon entry of lipids into
the duodenum to cause CCK release which is the main effector of gall bladder contrac-
tion [99]. This means that delivery of cholyl-insulin in protective capsules prior to a meal
could still be a feasible means of promoting absorption by the ileal mucosa. At present,
there are 13 initiatives underway using encapsulated insulin, insulin nanoparticles and
B29-PEG insulin to enhance the uptake of natural insulin by the intestinal mucosa [38].
Given the toxicity issues and the tendency for initiatives to be abandoned at an early
stage, the outlook for an oral insulin formulation is by no means certain [42]. So, it may
be timely to consider a new approach in the form of a cholyl-insulin formulation by which
absorption is achieved by secondary active transport rather than by passive diffusion and
is not dependent upon protease inhibitors or permeation enhancers (Table 1). This may
constitute a more productive avenue for further development.
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